New therapy update. Inspra (eplerenone tablets).
New therapy update. Inspra (eplerenone tablets).
复制标题
DOI：
10.1111/j.1527-5299.2003.03306.x
复制
发表时间：
2003-11-01
期刊：
影响因子：
--
通讯作者：
Kloner, Robert A
中科院分区：
文献类型：
--
作者：
Kloner, Robert A
Please try later.
Inspra (eplerenone tablets) is an aldosterone antagonist that is now indicated for improving survival in patients who develop congestive heart failure after myocardial infarction. In a major trial it reduced mortality rate by 15% in patients who were already on standard therapy. The drug is also approved for the treatment of hypertension either alone or in combination with other antihypertensive agents. Eplerenone is contraindicated if the serum potassium is greater than 5.5 mEq/L at initiation, creatinine clearance is≤ 30 mL/min, and with concomitant use of potent CYP3A4 inhibitors.